Cambrex Corporation announced an investment to expand chemical and analytical development capabilities at its Charles City, Iowa plant. 

The expansion consists of the construction of an additional 2,000 sq.ft. of laboratory space for development projects, and will support the hiring of an additional 14 chemists. The building, installation, and validation of equipment is expected to be completed by Q1 2018.

“The Charles City site has seen multiple investments and expansions in manufacturing capacity over the past five years to meet market demand, and this in turn, has led to us needing to increase the capacity of the supporting development and analytical functions,” commented Joe Nettleton, vice president US Operations, Cambrex. 

Cambrex’s Charles City, Iowa facility is located on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.